Impact of Histological Remission for Predicting Clinical Relapse in Crohn’s Disease: A Post Hoc Analysis of the Prospective STORI Cohort - Summary - MDSpire

Impact of Histological Remission for Predicting Clinical Relapse in Crohn’s Disease: A Post Hoc Analysis of the Prospective STORI Cohort

  • By

  • Catherine Reenaers

  • Diana Enea

  • Marie Nachury

  • David Laharie

  • Yoram Bouhnik

  • Mathurin Fumery

  • Jean-Marc Gornet

  • Aurélien Amiot

  • Romain Altwegg

  • Martine de Vos

  • Philippe Marteau

  • Arnaud Bourreille

  • Stéphane Nancey

  • Stéphanie Viennot

  • Edouard Louis

  • Magali Svrcek

  • November 2, 2024

  • 0 min

Share

Objective:

To examine the impact of histological inflammation on clinical relapse risk in Crohn’s disease (CD) and explore the relationship between histology, endoscopic scores, and biomarkers, including their predictive value.

Key Findings:
  • Histological remission rates were 46% (Nancy), 55% (Robarts), 61% (Geboes), and 41% (IBD-DCA).
  • 46% of patients experienced clinical relapse: 37% with histological remission and 56% without (Nancy score).
  • Histological scores did not predict clinical relapse; only fecal calprotectin was a significant predictor (p = 0.029).
Interpretation:

Despite correlations with endoscopic findings and biomarkers, histological scores do not predict clinical relapse in CD patients in remission, suggesting they are not suitable for assessing relapse risk in clinical practice.

Limitations:
  • Study limited to a specific cohort and may not generalize to all CD patients.
  • Potential biases in histological assessment due to subjective interpretation by pathologists, which may affect the reliability of the results.
Conclusion:

Histological scores are not recommended for clinical practice to assess relapse risk in Crohn’s disease patients.

Original Source(s)

Impact of Histological Remission for Predicting Clinical Relapse in Crohn’s Disease: A Post Hoc Analysis of the Prospective STORI Cohort

  • by Catherine Reenaers, Diana Enea, Marie Nachury, David Laharie, Yoram Bouhnik, Mathurin Fumery, Jean-Marc Gornet, Aurélien Amiot, Romain Altwegg, Martine de Vos, Philippe Marteau, Arnaud Bourreille, Stéphane Nancey, Stéphanie Viennot, Edouard Louis, Magali Svrcek

  • November 2, 2024

Related Content

Progression of Coronary Calcium Detected on Routine Chest CT Enhances Cardiovascular Risk Assessment in Individuals with Inflammatory Bowel Disease: Findings from a Multicenter Study

This Week’s Biopharma News: Amgen Deepens US Manufacturing Push

The company adds $300 million to its Puerto Rico biologics site as Pfizer reports Phase 3 myeloma data, J&J advances a dual-pathway IBD antibody, and BioNTech streamlines production

  • May 12, 2026

  • 7 min
Editorial: Volume II of the Community Series on Gut Microbiota and Immune Interactions in Intestinal Disorders